Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin.

Rice FL, Houk G, Wymer JP, Gosline SJC, Guinney J, Wu J, Ratner N, Jankowski MP, La Rosa S, Dockum M, Storey JR, Carroll SL, Albrecht PJ, Riccardi VM.

PLoS One. 2019 May 20;14(5):e0216527. doi: 10.1371/journal.pone.0216527. eCollection 2019.

2.

Considerations for development of therapies for cutaneous neurofibroma.

Verma SK, Riccardi VM, Plotkin SR, Weinberg H, Anderson RR, Blakeley JO, Jarnagin K, Lee J.

Neurology. 2018 Jul 10;91(2 Supplement 1):S21-S30. doi: 10.1212/WNL.0000000000005791.

PMID:
29987132
3.

The biology of cutaneous neurofibromas: Consensus recommendations for setting research priorities.

Brosseau JP, Pichard DC, Legius EH, Wolkenstein P, Lavker RM, Blakeley JO, Riccardi VM, Verma SK, Brownell I, Le LQ.

Neurology. 2018 Jul 10;91(2 Supplement 1):S14-S20. doi: 10.1212/WNL.0000000000005788.

PMID:
29987131
4.

Cutaneous neurofibromas: Current clinical and pathologic issues.

Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM, Miller DC, Huson S, Peltonen J, Rosenberg A, Carroll SL, Verma SK, Mautner V, Upadhyaya M, Stemmer-Rachamimov A.

Neurology. 2018 Jul 10;91(2 Supplement 1):S5-S13. doi: 10.1212/WNL.0000000000005792.

PMID:
29987130
5.

Prevalence and clinicopathological characteristics of lipomatous neurofibromas in neurofibromatosis 1: An investigation of 229 cutaneous neurofibromas and a systematic review of the literature.

Rozza-de-Menezes RE, Brum CAI, Gaglionone NC, de Sousa Almeida LM, Andrade-Losso RM, Paiva BVB, Faveret PLS, da Silva AV, Siqueira OHK, Riccardi VM, Cunha KS.

J Cutan Pathol. 2018 Oct;45(10):743-753. doi: 10.1111/cup.13315. Epub 2018 Aug 1. Review.

PMID:
29959804
6.

Amusia and its electrophysiological correlates in neurofibromatosis type 1.

Cota BCL, Fonseca JGM, Rodrigues LOC, Rezende NA, Batista PB, Riccardi VM, Resende LM.

Arq Neuropsiquiatr. 2018 May;76(5):287-295. doi: 10.1590/0004-282X20180031.

7.

The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.

Blakeley JO, Bakker A, Barker A, Clapp W, Ferner R, Fisher MJ, Giovannini M, Gutmann DH, Karajannis MA, Kissil JL, Legius E, Lloyd AC, Packer RJ, Ramesh V, Riccardi VM, Stevenson DA, Ullrich NJ, Upadhyaya M, Stemmer-Rachamimov A.

Am J Med Genet A. 2017 Jun;173(6):1714-1721. doi: 10.1002/ajmg.a.38239. Epub 2017 Apr 24.

8.

Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1.

Uusitalo E, Rantanen M, Kallionpää RA, Pöyhönen M, Leppävirta J, Ylä-Outinen H, Riccardi VM, Pukkala E, Pitkäniemi J, Peltonen S, Peltonen J.

J Clin Oncol. 2016 Jun 10;34(17):1978-86. doi: 10.1200/JCO.2015.65.3576. Epub 2016 Feb 29.

PMID:
26926675
9.

Lower fasting blood glucose in neurofibromatosis type 1.

Martins AS, Jansen AK, Rodrigues LO, Matos CM, Souza ML, de Souza JF, Diniz Mde F, Barreto SM, Diniz LM, de Rezende NA, Riccardi VM.

Endocr Connect. 2016 Jan;5(1):28-33. doi: 10.1530/EC-15-0102. Epub 2015 Dec 2.

10.

Ketotifen suppression of NF1 neurofibroma growth over 30 years.

Riccardi VM.

Am J Med Genet A. 2015 Jul;167(7):1570-7. doi: 10.1002/ajmg.a.37045. Epub 2015 May 14.

PMID:
25974154
11.

Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues.

Rauen KA, Huson SM, Burkitt-Wright E, Evans DG, Farschtschi S, Ferner RE, Gutmann DH, Hanemann CO, Kerr B, Legius E, Parada LF, Patton M, Peltonen J, Ratner N, Riccardi VM, van der Vaart T, Vikkula M, Viskochil DH, Zenker M, Upadhyaya M.

Am J Med Genet A. 2015 Jan;167A(1):1-10. doi: 10.1002/ajmg.a.36793. Epub 2014 Nov 12.

12.

Update from the 2013 International Neurofibromatosis Conference.

Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, Parkinson DB, Stemmer-Rachamimov AO, Van Raamsdonk CD, Riccardi VM, Rosser T, Schindeler A, Smith MJ, Stevenson DA, Ullrich NJ, van der Vaart T, Weiss B, Widemann BC, Zhu Y, Bakker AC, Lloyd AC.

Am J Med Genet A. 2014 Dec;164A(12):2969-78. doi: 10.1002/ajmg.a.36754. Epub 2014 Sep 24. No abstract available.

13.

The neurofibromatosis: which one and why?

Riccardi VM.

Arq Neuropsiquiatr. 2014 Mar;72(3):177-8. No abstract available.

14.

Progressive disorders and associated complications.

Riccardi VM.

Am J Med Genet A. 2013 Apr;161A(4):658. doi: 10.1002/ajmg.a.35846. Epub 2013 Feb 26. No abstract available.

PMID:
23444255
15.

Duplications, deletions, and single-nucleotide variations: the complexity of genetic arithmetic.

Riccardi VM, Lupski JR.

Genet Med. 2013 Mar;15(3):172-3. doi: 10.1038/gim.2012.124. Epub 2012 Oct 4. No abstract available.

PMID:
23037932
16.

Clinical characteristics predicting internal neurofibromas in 357 children with neurofibromatosis-1: results from a cross-selectional study.

Sbidian E, Hadj-Rabia S, Riccardi VM, Valeyrie-Allanore LL, Barbarot S, Chosidow O, Ferkal S, Rodriguez D, Wolkenstein P, Bastuji-Garin S.

Orphanet J Rare Dis. 2012 Sep 3;7:62. doi: 10.1186/1750-1172-7-62.

17.

The importance of advanced parental age in the origin of neurofibromatosis type 1.

Snajderova M, Riccardi VM, Petrak B, Zemkova D, Zapletalova J, Mardesic T, Petrakova A, Lanska V, Marikova T, Bendova S, Havlovicova M, Kaluzova M.

Am J Med Genet A. 2012 Mar;158A(3):519-23. doi: 10.1002/ajmg.a.34413. Epub 2012 Feb 2.

PMID:
22302476
18.

S100B and neurofibromin immunostaining and X-inactivation patterns of laser-microdissected cells indicate a multicellular origin of some NF1-associated neurofibromas.

Tucker T, Riccardi VM, Brown C, Fee J, Sutcliffe M, Vielkind J, Wechsler J, Wolkenstein P, Friedman JM.

J Neurosci Res. 2011 Sep;89(9):1451-60. doi: 10.1002/jnr.22654. Epub 2011 Jun 14.

PMID:
21674567
19.

Different patterns of mast cells distinguish diffuse from encapsulated neurofibromas in patients with neurofibromatosis 1.

Tucker T, Riccardi VM, Sutcliffe M, Vielkind J, Wechsler J, Wolkenstein P, Friedman JM.

J Histochem Cytochem. 2011 Jun;59(6):584-90. doi: 10.1369/0022155411407340. Epub 2011 Apr 27.

20.

Genotype-phenotype correlations in the genomic age: concordance in monozygous twin pairs.

Riccardi VM.

Am J Med Genet A. 2011 Mar;155A(3):476-7. doi: 10.1002/ajmg.a.33850. Epub 2011 Feb 18. No abstract available.

PMID:
21337691
21.

Neurofibromatosis type 1 is a disorder of dysplasia: the importance of distinguishing features, consequences, and complications.

Riccardi VM.

Birth Defects Res A Clin Mol Teratol. 2010 Jan;88(1):9-14. doi: 10.1002/bdra.20616. Review.

PMID:
19691086
22.

Hands down: reflecting on the 50th anniversary of the description of Trisomy 21.

Riccardi VM.

Genet Med. 2009 Sep;11(9):622-3. doi: 10.1097/GIM.0b013e3181b2e36f. No abstract available.

PMID:
19690508
23.

Diagnostic and management considerations posed by multiple café au lait spots.

Riccardi VM.

Arch Dermatol. 2009 Aug;145(8):929-30. doi: 10.1001/archdermatol.2009.180. No abstract available.

PMID:
19687427
24.
25.

Screening school-aged children for neurofibromatosis 1: dermatology or economics and public policy?

Riccardi VM.

Arch Dermatol. 2005 Jan;141(1):78-9. No abstract available.

PMID:
15655147
26.

Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: a cohort study of 703 patients.

Khosrotehrani K, Bastuji-Garin S, Riccardi VM, Birch P, Friedman JM, Wolkenstein P.

Am J Med Genet A. 2005 Jan 1;132A(1):49-53.

PMID:
15523617
27.

Analysis of neurofibromatosis 1 (NF1) lesions by body segment.

Palmer C, Szudek J, Joe H, Riccardi VM, Friedman JM.

Am J Med Genet A. 2004 Mar 1;125A(2):157-61.

PMID:
14981716
28.

Café au lait spots: the pediatrician's perspective.

Tekin M, Bodurtha JN, Riccardi VM.

Pediatr Rev. 2001 Mar;22(3):82-90. Review. No abstract available.

PMID:
11230626
29.

The vasculopathy of NF1 and histogenesis control genes.

Riccardi VM.

Clin Genet. 2000 Nov;58(5):345-7. No abstract available.

PMID:
11140832
30.

Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer.

Airewele GE, Sigurdson AJ, Wiley KJ, Frieden BE, Caldarera LW, Riccardi VM, Lewis RA, Chintagumpala MM, Ater JL, Plon SE, Bondy ML.

Genet Epidemiol. 2001 Jan;20(1):75-86.

PMID:
11119298
31.

Associations of clinical features in neurofibromatosis 1 (NF1).

Szudek J, Birch P, Riccardi VM, Evans DG, Friedman JM.

Genet Epidemiol. 2000 Dec;19(4):429-39.

PMID:
11108651
32.

Of mass and men: neurofibromas and histogenesis.

Riccardi VM.

Arch Dermatol. 2000 Oct;136(10):1257-8. Review. No abstract available.

PMID:
11030773
33.

Malignant peripheral nerve sheath tumors in neurofibromatosis 1.

King AA, Debaun MR, Riccardi VM, Gutmann DH.

Am J Med Genet. 2000 Aug 28;93(5):388-92.

PMID:
10951462
34.

Histogenesis control genes and neurofibromatosis 1.

Riccardi VM.

Eur J Pediatr. 2000 Jul;159(7):475-6. No abstract available.

PMID:
10923216
35.

Growth curves for height and head circumference.

Riccardi VM.

Am J Med Genet. 2000 Jun 19;92(5):369. No abstract available.

PMID:
10861671
36.

Histogenesis control genes: embryology, wound-healing, and NF1.

Riccardi VM.

Teratology. 2000 Jul;62(1):4. No abstract available.

PMID:
10861625
37.

Modern medicine; modern consumerism.

Riccardi VM.

Adm Radiol J. 1998 Nov;17(11):10-3.

PMID:
10345001
38.

Guidelines of care for neurofibromatosis type 1. American Academy of Dermatology Guidelines/Outcomes Committee.

Eichenfield LF, Levy ML, Paller AS, Riccardi VM.

J Am Acad Dermatol. 1997 Oct;37(4):625-30. No abstract available.

PMID:
9344204
39.

Hair whorl as an indicator of a mediastinal plexiform neurofibroma.

Pivnick EK, Lobe TE, Fitch SJ, Riccardi VM.

Pediatr Dermatol. 1997 May-Jun;14(3):196-8.

PMID:
9192411
40.
41.

The ocular presentation of neurofibromatosis 2.

Ragge NK, Baser ME, Riccardi VM, Falk RE.

Eye (Lond). 1997;11 ( Pt 1):12-8.

PMID:
9246269
42.

Neurofibromatosis type 1--an update and review for the primary pediatrician.

Goldberg Y, Dibbern K, Klein J, Riccardi VM, Graham JM Jr.

Clin Pediatr (Phila). 1996 Nov;35(11):545-61. Review.

PMID:
8953130
43.

Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations.

Baser ME, Mautner VF, Ragge NK, Nechiporuk A, Riccardi VM, Klein J, Sainz J, Pulst SM.

Neurology. 1996 Nov;47(5):1269-77.

PMID:
8909442
44.

Phenotypic variability in monozygotic twins with neurofibromatosis 2.

Baser ME, Ragge NK, Riccardi VM, Janus T, Gantz B, Pulst SM.

Am J Med Genet. 1996 Sep 6;64(4):563-7.

PMID:
8870923
45.

Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease.

Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Michels V, Riccardi VM, Weksberg R, Kitamura K, Bradburn JM, Hall BD, Propping P, Rouleau GA.

Am J Hum Genet. 1996 Aug;59(2):331-42.

46.

Ocular abnormalities in neurofibromatosis 2.

Ragge NK, Baser ME, Klein J, Nechiporuk A, Sainz J, Pulst SM, Riccardi VM.

Am J Ophthalmol. 1995 Nov;120(5):634-41.

PMID:
7485365
47.

Skin, blood, nerve cells, and heritability. New lessons from neurofibromatosis type 1.

Riccardi VM.

Arch Dermatol. 1995 Aug;131(8):944. No abstract available.

PMID:
7632067
49.

Familial multiple cafe au lait spots.

Arnsmeier SL, Riccardi VM, Paller AS.

Arch Dermatol. 1994 Nov;130(11):1425-6.

PMID:
7979446
50.

Neurofibromatosis and related tumors. Natural occurrence and animal models.

Riccardi VM, Womack JE, Jacks T.

Am J Pathol. 1994 Nov;145(5):994-1000. Review. No abstract available.

Supplemental Content

Loading ...
Support Center